Marinus Pharmaceuticals, Inc. has entered into an agreement with CyDex Pharmaceuticals, Inc. for the clinical use of Captisol, a patent protected, uniquely modified cyclodextrin, whose chemical structure was designed to improve solubility, stability, bioavailability, and dosing of active pharmaceutical ingredients. Marinus intends to evaluate optimizing its intravenous dose form of ganaxolone with Captisol.

“We are pleased to announce this important step towards optimizing our IV formulation of ganaxolone for inpatient, acute care treatment situations,” said Christopher M. Cashman, President and CEO of Marinus Pharmaceuticals, Inc. “Ganaxolone IV is planned to be available for human clinical testing next year and complements our existing capsule and liquid suspension dose forms presently in the clinic.”